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Introduction. Given the lack of independent analyses comparing numerous pharmacotherapies for osteoporosis, the
study objective was to identify the optimal osteoporosis treatment based on a woman’s age, fracture history, and
ability to tolerate oral bisphosphonates adopting practices recommended in the recently revised Canadian guidelines.
Methods. A cost utility analysis from the health care system perspective compared alendronate, etidronate, risedro-
nate, zoledronate, denosumab, and no pharmacotherapy using a Markov model incorporating data on fracture risk
and their associated costs, mortality, and disutility and treatment effect. Stratified analysis was conducted based on
age, fracture history, and ability to tolerate oral bisphosphonates. Expected lifetime outcomes were obtained through
probabilistic analysis with scenario analyses addressing methodological and structural uncertainty. Results. For
women able to tolerate oral bisphosphonates, risedronate and etidronate were dominated. Compared to no therapy,
alendronate was either dominant or was associated with a low incremental cost per QALY (quality-adjusted life
years) gained (ICER)—less than CAN$3,751 based on age and fracture history. In comparison with alendronate,
both zoledronate and denosumab were either dominated or associated with a high ICER—greater than
CAN$660,000 per QALY. For women unable to tolerate bisphosphonates, dependent on age and fracture history,
the ICER for zoledronate versus no therapy ranged from CAN$17,770 to CAN$94,365 per QALY. For all strata,
denosumab was dominated by zoledronate or had an ICER greater than CAN$3.0 million. Scenario analyses found
consistent findings. Conclusions. Based on a threshold of CAN$50,000 per QALY, alendronate is optimal for osteo-
porotic women who can tolerate oral bisphosphonates regardless of age or fracture history. For women unable to
tolerate oral bisphosphonates, zoledronate is optimal for women with previous fracture or aged 80 to 84 or over 90
with no previous fracture.
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Osteoporosis is a progressive bone disease characterized
by low bone mass that increases bone fragility leading to
an increase in fracture risk.1 Osteoporosis can be diag-
nosed either by the presence of fragility fractures or
based on the World Health Organization criteria relating
to bone mass: having a bone mineral density (BMD) that
is at least 2.5 standard deviations (SD) below the mean
This Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE
and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
School of Epidemiology and Public Health, University of Ottawa,
Ottawa, Ontario, Canada; and Division of Health Sciences,
Department of Clinical Sciences, College of Health & Life Sciences,
Brunel University London, Uxbridge, UK. The author declared no
potential conflicts of interest with respect to the research, authorship,
and/or publication of this article. The author received no financial sup-
port for the research, authorship, and/or publication of this article.
Corresponding Author
Doug Coyle, School of Epidemiology and Public Health, Faculty of
Medicine, University of Ottawa, 600 Peter Morand Cres., Ottawa,
Ontario K1G 5Z3, Canada; Telephone: (613) 562-5800
(dcoyle@uottawa.ca).
peak bone mass of an average young female.2 In Canada,
the prevalence of osteoporosis in postmenopausal women
increases from approximately 6% in those aged 50 to 59
years to over 40% in those aged over 80.3
The most common fractures associated with osteo-
porosis are fractures of the hip, vertebrae, or wrist. The
major source of morbidity from osteoporosis arises from
hip fractures, which are also associated with higher costs
and greater mortality.4,5 Alongside the increasing preva-
lence of osteoporosis, the risk of fracture for an osteo-
porotic women increases with age.3,6 Fracture risk is also
related to previous history of fracture and the degree of
low bone mass.2,7
The annual health care cost in 2010 associated with
osteoporosis in Canada was CAN$2.3 billion with an
additional CAN$1.6 billion for associated use of long-
term care facilities.4 The cost of treating hip fractures
comprised more than half of the acute care costs associ-
ated with osteoporosis.4 Pharmacological treatments for
osteoporosis covered in Ontario, the most populous of
Canadian provinces, are bisphosphonates (alendronate,
etidronate, risedronate, and zoledronate) and the
RANKL (receptor activator of nuclear factor kappa-B
ligand) inhibitor—denosumab. The annual costs of
osteoporosis drug treatments vary considerably although
such costs may by partly offset by reducing the economic
burden of fracture.
In April 2017, the Canadian Agency for Drugs and
Technologies in Health (CADTH) released the 4th edi-
tion of the Canadian Guidelines for the Economic
Evaluation of Health Technologies.8 The Guidelines rep-
resent a major revision from the previous edition, which
was published in 2006, to reflect a number of methodolo-
gical advances that haven taken place in the conduct of
economic evaluations and the adoption of a cohesive
and appropriate theoretical framework with emphasis on
the role of economic evaluation as an input to decision-
making processes.9
Within Canada, economic evaluations are conducted
primarily to facilitate health care decisions within a pub-
licly funded system. Thus, developers of the guidelines
recognized the need to adopt a social decision-making
approach as the theoretical paradigm to root the guide-
lines with the assumption that decision makers within
the publicly funded system primarily wish to maximize
population health given their budget constraints.
Changes within the Guidelines were therefore made to
be consistent with the adoption of this paradigm.
Significant revisions related to specification of the deci-
sion problem, the need for stratified analysis, adopting a
theoretically driven discount rate, and the use of
probabilistic analysis in the base case: with greater clarity
provided in the recommendation for the adoption of a
health care system perspective. The objective of this
study was to assess the cost-effectiveness of the various
pharmacotherapies and identify which treatments are
optimal, depending on a woman’s age and fracture his-
tory and for the subgroup of women who may not be
able to tolerate oral bisphosphonates using methods con-
sistent with the revised Canadian guidelines. Thus, anal-
ysis was based on defining the relevant decision problem
and then cost-effectiveness was assessed with appropriate
consideration of uncertainty and variability.
Methods
Decision Problem
The study was designed to address specific decision prob-
lems as required within the recently revised Canadian
Guidelines for Economic Evaluation.8 The Guidelines
replaced an existing section titled ‘‘Study Objective’’ with
a section titled ‘‘Decision Problem.’’ This change recog-
nizes that economic evaluations are primarily designed
to inform decision making and specification of a decision
problem provides a cohesive basis from which to design
the research. The decision problem requires specification
of the perspective, interventions, metrics (e.g., costs, out-
comes) used to compare the interventions and time
horizon.
The decision problem that this analysis addresses is
which of the currently available pharmacotherapies for
osteoporosis a provincial health ministry, as the payer of
prescription medications, should cover within a provin-
cial formulary. Analysis incorporates all pharmacothera-
pies for osteoporosis currently covered by Canadian
provincial formularies (alendronate, denosumab, etidro-
nate, risedronate, and zoledronate). As recommended
within the Guidelines, analysis includes a no active phar-
macotherapy alternative given that in certain patient
populations none of the existing pharmacotherapies may
be cost-effective. This, in addition, reflects the previous
restrictive listing basis for bisphosphonates in Ontario.
For all comparators, patients may in addition be taking
calcium and/or vitamin D as is typical in osteoporosis
clinical studies. The cost-effectiveness of treatments may
vary by patient characteristic. A major change in the
Guidelines is in the handling of heterogeneity. The cost-
effectiveness of an intervention depends on the charac-
teristics of the population for which it is being evaluated.
As the existence of heterogeneity will lead to different
conclusions, stratified analysis that requires the popula-
tion to be parsed into smaller, more homogeneous
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subgroups is required.10,11 The requirement for stratified
analysis directly relates to the adoption of the social
decision-making viewpoint. Within this study, there are
multiple decision problems relating to various patient
strata. For illustration, a base case analysis is presented
for a cohort of 70- to 74-year-old osteoporotic women
with no previous fracture who are able to tolerate oral
bisphosphonates. The analysis is conducted, however,
for different patients started based on the cohort’s initial
age group (65–69, 70–74, 75–79, 80–84, 85–89, 90+),
fracture history (no previous fracture and previous frac-
ture), and whether or not the individual can tolerate oral
bisphosphonates. Intolerance or inability to take oral
bisphosphonates is based on the definition from the
Ontario Drug Benefit program: either hypersensitivity,
abnormalities of the esophagus, or an inability to stand
or sit upright for at least 30 minutes.
Given the focus on maximizing population, analysis
takes the form of a cost utility analysis with a lifetime
time horizon, where outcomes are expressed in terms of
quality-adjusted life years (QALYs) with analysis pre-
sented in terms of the incremental cost per QALY gained
(ICER).8
Based on the preferences of the relevant decision mak-
ers, analysis adopts the perspective of the health and
social care system in that the costs of health, social ser-
vices, and long-term care (LTC) are included.8 Adoption
of a wider perspective would require that health care
decision makers would be willing to trade health gains
for benefits to other sectors.
For the base case analysis, costs and benefits were dis-
counted at 1.5% per annum.8 Scenario analysis was con-
ducted with discounting at 0%, 3%, and 5%.8 The
revised Guidelines recommended adoption of a social
discount rate represented by the real rate of interest on
provincial government bonds.12 The revised rate is based
on the available empirical evidence.12
Model Design
The analysis was conducted using a decision analytic
model for osteoporosis developed based on the most
recently available data relevant to the Canadian popula-
tion. The model used is an update of a model employed
in several previous analyses and follows guidelines both
for the design of economic models in general and for the
design of economic models specific to osteoporosis.8,13–16
The major previous use of the model was in a health
technology assessment conducted by CADTH, which
examined the cost effectiveness of teriparatide compared
to bisphosphonates, which informed provincial decisions
relating to this product.14 The model was chosen due to
it being independent and to its convergent validity in that
it replicates the population-level data available from the
data sources. Further details of calibration and valida-
tion are provided in an online appendix.
Analysis was conducted using a Markov model with
1-year cycle length and a lifetime horizon. The cycle
length was chosen based on the unlikeliness of an indi-
vidual having more than one hip fracture (the event asso-
ciated with the greatest cost and disutility) in 1 year. The
model incorporates the sequelae associated with osteo-
porosis (e.g., fracture) and the transition of women
through different states related to the development of
osteoporosis, history of fracture, and residential status.
A schematic of the model is provided in Figure 1.
For the base case the cohort will start the model in the
no fracture history state. For each year, a proportion of
the cohort can transition into a fracture-related state (hip,
wrist, or vertebral), can die, or remain in the no fracture
history state. The proportion of the cohort who enter the
hip fracture state can in the next cycle either transition
into the hip fracture post fracture year 1 state, can die, or
can have a repeat hip fracture. The proportion of the
cohort in the wrist, vertebral, or hip fracture post year 1
state can transition into any of the fracture event states,
die, or enter the previous fracture history state.
The model is populated with relevant transition prob-
abilities and estimates of the costs and utilities associated
with each health state3,4,6,7,17–35 (Table 1). Data sources
were obtained through review of the available literature
and focused on identifying the most recent relevant and
appropriate data from a Canadian context.36 Expected
values of costs and QALYs for each pharmacotherapy for
each patient strata are obtained through probabilistic anal-
ysis using Monte Carlo simulation.8 The same technique is
used for all strata-specific analyses and all scenario analy-
ses. The model is developed within a Microsoft Excel
workbook.
Transition Probabilities
Given the structure of the model outlined above, the fol-
lowing transition probabilities are required to allow a
simulation of progression through the model: probabil-
ities of hip, wrist, and spine fracture; probability of devel-
oping osteoporosis (which is required for calibration
purposes as described in the online appendix); probabil-
ity of being admitted to LTC; and probability of death.
Each of these probabilities will vary by a number of
factors. The probability of developing osteoporosis will
increase with age.3 The probability of fracture increases
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with age, residence in LTC, and previous history.6,7,30,31
Admission to LTC increases with age.32 The probability
of death increases with age, incidence of fracture, and
residence in LTC.5,17,33–35 Specific data on probabilities
by risk factors were often unavailable. However, data for
alternative parameters were available, which allowed
computation of the necessary parameters through cali-
bration of the model. Further details of the required cali-
bration and convergent validity of the model are
provided in the online appendix.
Costs
For each particular state within the decision model, there
is an associated estimate of costs (adjusted to 2017
Canadian dollars). Consistent with the adopted perspec-
tive, costs relate to the management of fractures, osteo-
porosis, and subsequent admission to LTC. Scenario
analysis included the costs of additional non-osteoporosis
health care.
The cost of the health care resources associated with the
treatment of a hip fracture in Ontario including immediate
acute care, rehabilitation, and institutionalization were
obtained from an analysis of health care administrative
claims and billing data available at the Institute for Clinical
Evaluative Sciences.18,19 The costs of treating a woman
with vertebral and wrist fractures that required hospitaliza-
tion were obtained from an analysis of administrative data
held by the Ontario Case Costing Initiative.20 Resource use
associated with treating a women with vertebral and wrist
fractures that do not require hospitalization were assumed
to be the same as from a previous Canadian economic
study with current costs obtained from a provincial minis-
try of health.21,37,38 The proportions of women with these
fractures requiring hospitalization was derived from the
incidence data of fracture from CaMos and a recent burden
of illness study.4,6
Drug costs were obtained from the Ontario Drug
Benefit Formulary.22 The yearly cost of each product
was obtained by summing the acquisition costs of the
medication, an additional 8% markup, and the appropri-
ate number of dispensing fees at a cost of CAN$8.83
each (4 for alendronate, etidronate, and risedronate; 2
for zoledronate; and 1 for denosumab).
Utilities
Utility values for women with normal health status were
obtained by age from the 2014 Canadian Community
Health Survey.23 Utility multipliers associated with hip
and wrist fractures and vertebral fractures not requiring
hospitalization were derived from a systematic review of
utility values for fractures24,25 (Table 1).
Treatment-Specific Parameters
The analysis plan was to adopt the effect of alternative
treatments on the risks of fractures from a published net-
work meta-analysis. On review, a number of meta-
Figure 1 Schematic of Markov model. Schematic illustrates all possible transitions form one cycle to the next. Patients with a hip
fracture will either enter into the post-fracture state for 1 year, have a repeat hip fracture, or die. Note that the schematic does
not illustrate transitions relating to movement in residential status. Patients can transition from living to the community to living
in long-term care from any health state.
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Table 1 Parameter Estimatesa
Parameter Base Value Probability Distribution Reference
Natural history data
Relative risk of wrist fracture for each 1 SD decrease in bone
density
1.4 Lognormal (1.4, 1.6) 7
Relative increase of hip fracture for 1 each SD decrease in
bone density
2.6 Lognormal (2, 3.5) 7
Relative increase of vertebral fracture for each 1 SD decrease
in bone density
1.8 Lognormal (1.1, 2.7) 7
Relative risk of hip fracture given previous fracture 2 Lognormal (1.9, 2.2) 30
Relative risk of wrist fracture given previous fracture 1.9 Lognormal (1.3, 2.8) 30
Relative risk of spine fracture given previous fracture 2 Lognormal (1.6, 2.4) 30
Relative risk of hip fracture given living in LTC 1.5 Lognormal (1.3, 1.7) 31
Relative risk of mortality post hip fracture and living in LTC 3.24 Lognormal (2.37, 4.43) 34
Relative risk of mortality post vertebral fracture 1.16 Lognormal (1.03, 1.3) 35
Relative risk of mortality post hip fracture 2.87 Lognormal (2.52, 3.27) 5
Relative risk of mortality given living in LTC 1.16 Lognormal (1.1, 1.2) 17
Average peak bone mass 0.857 Normal (0.857, 0.022) 3
Bone mass by age
50–59 0.759 Normal (0.759, 0.003) 3
60–69 0.695 Normal (0.695, 0.003) 3
70–79 0.661 Normal (0.661, 0.003) 3
80+ 0.593 Normal (0.593, 0.006) 3
Standard deviation for peak bone mass 0.125 3





Annual probability of vertebral fracture
50–59 0.0018 Beta (8.05, 4559.45) 6
60–69 0.0015 Beta (4.01, 2626.34) 6
70–79 0.0039 Beta (74.44, 18813.8) 6
80+ 0.0076 Beta (137.16, 17832.5) 6
Annual probability of wrist fracture
50–59 0.0031 Beta (14.08, 4550.05) 6
60–69 0.0062 Beta (16.18, 2613.58) 6
70–79 0.0086 Beta (309, 35802.22) 6
80+ 0.0076 Beta (137.16, 17832.5) 6
Annual probability of hip fracture
50–59 0.0003 Beta (2.12, 7215.24) 6
60–69 0.0018 Beta (4.84, 2623.84) 6
70–79 0.0024 Beta (45.71, 18834) 6
80+ 0.0064 Beta (115.92, 17861.69) 6
Proportion of women residing in LTC
65–69 0.01 Beta (8,952, 886,248) 32
70–74 0.023 Beta (15,235, 647,165) 32
75–79 0.057 Beta (29,372, 485,928) 32
80–84 0.136 Beta (57,120, 362,880) 32
.85 0.334 Beta (156,446, 311,954) 32
Proportion of women who are osteoporotic
50–59 0.060 Beta (1,196, 1,273) 3
60–69 0.183 Beta (1,505, 1,841) 3
70–79 0.269 Beta (991, 1,356) 3
.80 0.413 Beta (184, 313) 3
Mortality in general population (females)
50–54 0.0024 Beta (1,368,800, 1,372,100) 33




Parameter Base Value Probability Distribution Reference
60–64 0.0057 Beta (1,061,242, 1,067,300) 33
65–69 0.0091 Beta (887,055, 895,200) 33
70–74 0.0150 Beta (652,462, 662,400) 33
75–79 0.0254 Beta (502,196, 515,300) 33
80–84 0.0443 Beta (401,409, 420,000) 33
85–89 0.0789 Beta (265,173, 287,900) 33
.90 0.1772 Beta (148,523, 180,500) 33
Proportion of vertebral fractures by treatment requirement
Hospitalized 0.09 Dirichlet (18, 47, 132) 6
Physician care 0.24 6
No treatment 0.67 6
Proportion of wrist fractures requiring hospitalization 0.10 Beta (3,697, 33,341) 4
Treatment effectiveness
Relative reduction in hip fractures
Alendronate 0.59 Lognormal (0.29, 0.99) 26
Etidronate 1.02 Lognormal (0.12, 3.71) 26
Risedronate 0.78 Lognormal (0.44, 1.31) 26
Denosumab 0.67 Lognormal (0.24, 1.46) 26
Zoledronate 0.65 Lognormal (0.25, 1.33) 26
Relative reduction in wrist fractures
Alendronate 0.93 Lognormal (0.31, 2.51) 26
Etidronate 2.32 Lognormal (0.26, 8.13) 26
Risedronate 0.91 Lognormal (0.13, 3.06) 26
Denosumab 0.84 Lognormal (0.64, 1.11) 26
Relative reduction in vertebral fractures
Alendronate 0.54 Lognormal (0.4, 0.7) 26
Etidronate 0.64 Lognormal (0.31, 1.07) 26
Risedronate 0.66 Lognormal (0.48, 0.81) 26
Denosumab 0.33 Lognormal (0.23, 0.47) 26
Zoledronate 0.30 Lognormal (0.21, 0.43) 26
Treatment continuation rates
Alendronate (daily) 0.65 Beta (65, 35) 14
Etidronate 0.57 Beta (57, 43) 14
Risedronate (daily) 0.62 Beta (62, 38) 14
Relative reduction in noncompliance
Once weekly bisphosphonates versus once daily 0.719 Lognormal (0.7126, 0.7265) 27
Denosumab versus bisphosphonates 0.540 Lognormal (0.31, 0.93) 28
Zoledronate versus denosumab 1.256 Lognormal (1.15, 1.37) 29
Cost of health care events
Hip fracture—living in the community 50513.75 Gamma (50,514, 401) 18,19
Hip fracture—living in LTC 19582.77 Gamma (19,583, 403) 18,19
Hip fracture—women who die following fracture 12207.83 Gamma (12,208, 1429) 18,19
2nd year post hip fracture 5134.32 Gamma (5,134, 210) 18,19
Wrist fracture—ambulatory 411.40 Gamma (411, 4) 21
Wrist fracture—hospitalized 8557.40 Gamma (8,557, 435) 20
Vertebral fracture—ambulatory 612.40 Gamma (612, 10) 21
Vertebral fracture—hospitalized 12613.40 Gamma (12,613, 559) 20
No fracture—living in LTC 46301.57 Gamma (46,302, 953) 18,19
No fracture—living in community 9086.38 Gamma (9,086, 72) 18,19
Annual drug costs
Alendronate 153.66 Fixed 22
Etidronate 122.88 Fixed 22
Risedronate 180.31 Fixed 22
Denosumab 825.67 Fixed 22
Zoledronate 371.06 Fixed 22
(continued)
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analyses have been conducted. Given the decision prob-
lem that the study is addressing, the meta-analysis would
preferably be comprehensive in their inclusion of studies,
focused on osteoporotic women and cover at least the
comparators of interest. Based on these considerations
the most appropriate analysis was conducted by Hopkins
and colleagues.26 Analysis adopted estimates derived
from a Bayesian indirect treatment comparison with
odds ratios converted to relative risks based on preva-
lence in the placebo groups.26 The Hopkins study cov-
ered all major clinical trials in this area; however, it was
published prior to the publication of a companion study
to the FREEDOM study, which provides the sole evi-
dence of the effect of denosumab on wrist fractures.39,40
This new data were incorporated into the analysis. There
is currently no data relating to the impact of zoledronate
on wrist fractures, so the same incidence of wrist frac-
tures as with no therapy was assumed.
While the epidemiological data detailed above provide
evidence on probabilities across all ages, fracture history,
and time; data on treatment effectiveness are restricted
to single relative risks relating to the time horizon of the
clinical trials. Thus, analysis did make the assumption
that there would be a continuance of treatment effect for
the duration of therapy; however, given the duration of
clinical trials this assumption is likely valid.
Treatment duration was assumed to be a maximum of
5 years. There is evidence that patients experience contin-
ued reductions in the risk of fracture after stopping ther-
apy. Thus, the model allows for a fracture set time
whereby there is a linear reduction of benefit after the
curtailment of therapy up to a set period of time. Base
analysis assumed a set time of 2 years with scenario anal-
yses adopting a set time of 0 and 5 years.14,41–43
Adherence was incorporated into the model by
assuming that a proportion of patients would stop treat-
ment within 12 months of commencement—those who
continue would continue for the maximum duration of
treatment specified in the analysis. It is necessary to
incorporate differential adherence with pharmacothera-
pies based primarily on their frequency. Data on 12-
month adherence to daily alendronate, etidronate, and
risedronate were based on data for Ontario.14 Improved
adherence for weekly bisphosphonates versus daily was
modelled based on relative adherence rates from an anal-
ysis of administrative data.27 Improved adherence with
denosumab versus weekly bisphosphonates was mod-
elled based on data from a randomized controlled trial.28
The relative adherence with zoledronate versus denosu-
mab was modelled based on data from a recent retro-
spective observational study.29 Thus, annual adherence
rates adopted within the study were 57% for etidronate,
74.8% for weekly alendronate, 72.7% for weekly risedro-
nate, 86.4% for denosumab, and 82.9% for zoledronate.
Analysis
Analysis is presented according to the recent Canadian
guidelines.8 Given the objective of maximizing population
health, the Guidelines require that costs and outcomes
for each intervention must be obtained through probabil-
istic analysis given that deterministic analysis gives biased
estimates when there are nonlinear relationships among
input variables and outputs. The Guidelines, therefore,
require the use of probabilistic analysis within the base
case rather than as probabilistic sensitivity analysis.
Thus, the expected values for costs and QALYs were
obtained through probabilistic analysis using Monte
Table 1 (continued)
Parameter Base Value Probability Distribution Reference
Utility values
Women aged 65–69—no fracture 0.836 1 2 Lognormal (0.164, 0.004) 23
Women aged 70–74—no fracture 0.824 1 2 Lognormal (0.176, 0.004) 23
Women aged 75–79—no fracture 0.792 1 2 Lognormal (0.208, 0.005) 23
Women aged .80—no fracture 0.712 1 2 Lognormal (0.288, 0.005) 23
Hip fracture—1st year—utility multiplier 0.7 1 2 Lognormal (0.3, 0.033) 24
Hip fracture—2nd year—utility multiplier 0.8 1 2 Lognormal (0.2, 0.071) 24
Vertebral fracture—hospitalized—utility multiplier 0.59 1 2 Lognormal (0.41, 0.094) 24
Wrist—utility multiplier 0.956 1 2 Lognormal (0.044, 0.036) 24
Vertebral fracture—not hospitalized—utility multiplier 0.909 1 2 Lognormal (0.091, 0.043) 25
LTC, long-term care; SD, standard deviation.
aBeta and gamma distributions depicted by shape and scale parameters. Dirichlet distribution depicted by concentration parameters. Normal
distributions depicted by mean and standard errors. Lognormal distribution depicted by upper and lower bounds of the 95% confidence interval.
Costs represent CAN$ in 2017.
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Carlo simulation.8 All input parameters except drug costs
were assumed to be random variables rather than fixed
values. Analysis involves re-running the model employing
different values for each data input randomly selected
from a probability density function that is characterized
by the mean value, a measure of dispersion (standard
error), and type of distribution. Standard distributions
were used for each data element: beta and Dirichlet distri-
butions for probabilities, 1 2 lognormal distributions for
utility values, lognormal distributions for relative effects,
and gamma distributions for cost data.44 Analysis was
based on a Monte Carlo simulation whereby 5,000 esti-
mates of the costs and QALYs for each treatment were
obtained, which was sufficient to obtain stable estimates
of each outcome.
As recommended by the Canadian guidelines, disag-
gregated results are presented both discounted and undis-
counted and a sequential analysis is conducted that
requires, first, exclusion of all dominated alternatives and
then, second, the estimation sequentially of the incremen-
tal cost per QALY gained (ICER) for a less costly com-
parator compared to the next most costly comparator.
The probability that a particular therapy is optimal
for different threshold values for a QALY is illustrated
by both a cost-effectiveness acceptability curve and a
cost-acceptability frontier.8
As recommended within the revised Guidelines, sce-
nario analyses were conducted to assess if the interpreta-
tion of the study results would change with a number of
alternative methodological assumptions detailed above.8
This is distinct from deterministic sensitivity analysis
whereby the expected value of particular inputs are chan-
ged to assess the impact on the study’s results and con-
clusions. The revised Guidelines do not recommend the
use of such analyses as they ignore the likelihood of the
alternative parameter values and, thus, do not demon-
strate the likelihood of the alternative results identified.
A further series of scenario analyses were conducted
such that they adopted assumptions similar to those
employed in the five previous manufacturer sponsored
studies that compared denosumab, risedronate, and alen-
dronate.41,45–48 These studies adopted a number of
assumptions favorable toward denosumab: selective and
outdated choice of effectiveness data more favorable
toward denosumab41,45–48; assuming the impact on mor-
tality of vertebral fractures would be equal48 or
greater41,45–47 when compared to hip fracture; much
higher costs for vertebral fracture41,45–47 (in some cases,
exceeding those of hip fracture45,46); a lack of clarity on
whether the model was fully calibrated especially with
respect to mortality41,45–48; and inclusion of the branded
cost for risedronate.45–48 A scenario analysis was con-
ducted for women aged 70 to 74 with previous fracture,
which partially assessed the impact of these assumptions
by adopting alternative relative effects, no calibration of
mortality, assuming the cost of vertebral fractures would
be 50% of the costs of hip fractures, assuming the impact
of an incident vertebral fracture on mortality would be
equal to that of hip fracture, and adopting branded costs
of risedronate.
Threshold analysis was conducted to ascertain the nec-
essary price reduction for zoledronate and denosumab
that would be required for these products to be consid-
ered optimal given an assumed maximum willingness to
pay for a QALY of CAN$50,000.49
Results
Analysis for Base Case Population
For the base case population, denosumab was the most
effective treatment in terms of QALYs and life years
gained (both discounted and undiscounted; Table 2).
However, the gain in discounted QALYs was 0.00015
when compared with zoledronate and 0.0016 when com-
pared with alendronate. Alendronate was associated with
lowest lifetime fracture costs and the lowest overall costs
of all pharmacotherapies. Alendronate was associated
with the lowest number of hip fractures, while denosu-
mab was associated with the lowest number of wrist frac-
tures and denosumab and zoledronate the lowest number
of vertebral fractures.
When compared to no therapy, alendronate was the
only therapy associated with an ICER less than
CAN$50,000 per QALY (Table 3). The ICER for alendro-
nate versus no therapy was $3,751 per QALY. The ICER
for zoledronate versus alendronate was CAN$666,285
per QALY, and the ICER for denosumab versus
zoledronate was CAN$12.9 million per QALY.
Risedronate and etidronate were all dominated by
alendronate as they were associated with fewer QALYs
and higher costs. The ICER for denosumab versus
alendronate was CAN$1.8 million.
The interpretation for decision makers of this result
would be the following. If their willingness to pay for a
QALY was less than CAN$3,751 per QALY, then for
this patient cohort, no therapy would be optimal. If their
willingness to pay for a QALY was between CAN$3,751
and CAN$666,285 per QALY, alendronate would be
optimal. If their willingness to pay for a QALY was
between CAN$666,285 and CAN$12.9 million per
QALY, zoledronate would be optimal. And finally, if
their willingness to pay for a QALY was greater than
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CAN$12.9 million per QALY, denosumab would be
optimal.
Figure 2a presents the probability that each therapy is
optimal based on the threshold value for a QALY rang-
ing from CAN$ 0 to CAN$100,000. For threshold values
of a QALY below CAN$2,165, no therapy has the high-
est probability of being optimal. For values above
CAN$2,165, alendronate has the highest probability of
being optimal; for values above CAN$12,000 the prob-
ability is greater than 50%. At a threshold value of
CAN$50,000 per QALY, the probability that each treat-
ment was optimal was 60.1% for alendronate, 13.8% for
risedronate, 10.3% for etidronate, 9.3% for zoledronate,
6.4% for no therapy, and 0.1% for denosumab. At
threshold value of a CAN$100,000, the probabilities
were 59.5% for alendronate, 14.1% for risedronate,
12.9% for zoledronate, 9.4% for etidronate, 3.9% for no
therapy, and 0.2% for denosumab.
Analysis by Patient Strata
Analysis by different strata found consistent results in
terms of their interpretation, although estimated ICERs
did vary by a woman’s age and fracture history (Table 4).
In every strata, alendronate either dominated no therapy
or was associated with an ICER of less than CAN$5,000
Table 2 Disaggregated Lifetime Results for 70- to 74-Year-Old Osteoporotic Women With No Previous Fracturea
No Therapy Alendronate Etidronate Risedronate Denosumab Zoledronate
Undiscounted Total lifetime costs $7,047 $7,078 $8,370 $7,468 $9,993 $8,057
QALYs 12.158 12.170 12.139 12.163 12.171 12.171
Treatment costs $ 0 $571 $363 $653 $3,469 $1,534
Fracture costs $7,047 $6,506 $8,007 $6,815 $6,524 $6,523
Hip fracturesb 126.4 117.4 141.2 122.4 118.1 117.9
Wrist fracturesb 162.5 164.4 261.1 175.4 152.2 160.4
Spine fracturesb 153.8 139.9 152.9 144.8 130.6 130.5
Life years 16.729 16.737 16.717 16.733 16.737 16.737
Discounted Total lifetime costs $6,048 $6,087 $7,297 $6,459 $8,928 $7,044
QALYs 10.671 10.681 10.654 10.675 10.683 10.682
Treatment costs $ 0 $556 $353 $635 $3,371 $1,492
Fracture costs $6,048 $5,532 $6,943 $5,823 $5,557 $5,552
Life years 14.562 14.568 14.552 14.565 14.568 14.568
aQALYs (quality adjusted life years), lifetime fractures per 1,000 women. Costs represent CAN$ in 2017.
bPer 1000 women.




No Therapy Sequential ICER ($/QALY Gained)
Nondominated therapies
No therapy $6,048 10.671
Alendronate $6,087 10.681 $3,751 $3,751
Zoledronate $7,044 10.682 $83,503 $666,285
Denosumab $8,928 10.683 $238,523 $12,958,077
Dominated therapies
Etidronate $7,297 10.654 Dominated by
no therapy
Dominated by no therapy, alendronate, risedronate,
and zoledronate
Risedronate $6,459 10.675 $85,557 Dominated by alendronate
Subject to extended dominance through no therapy and
zoledronate
ICER, incremental cost per QALY gained; QALY, quality-adjusted life year.
aCosts represent CAN$ in 2017.
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per QALY. For all strata, alendronate either dominated
zoledronate or the ICER for zoledronate versus alendro-
nate was greater than CAN$660,000 per QALY. In most
strata, alendronate dominated denosumab. In those
strata where denosumab was associated with more
QALYs than alendronate, the ICER for denosumab ver-
sus alendronate ranged from CAN$1.8 million to
CAN$8.0 million per QALY.
For women unable to tolerate oral bisphosphonates
for all strata, zoledronate either dominated denosumab
Figure 2 Cost-effectiveness acceptability curve and cost-effectiveness frontier for base population: (a) Cost-effectiveness
acceptability curve; (b) cost-effectiveness frontier.
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or the ICER for denosumab versus zoledronate was
greater than CAN$7.3 million per QALY. The ICER for
zoledronate versus no therapy was below CAN$50,000
for all women with previous fracture and for those
women without a previous fracture aged 80 to 84 and
over 90.
Scenario Analysis
The conclusions to be drawn from the results of the
scenario analysis did not differ from the base analysis
(Table 5). The ICER for alendronate versus no therapy
remained less than CAN$8,000 per QALY in all
scenarios. The ICER for zoledronate versus alendro-
nate remained greater than $600,000 for all relevant
scenarios. In the scenario analysis using assump-
tions more favorable to denosumab, the ICER for
denosumab versus alendronate for those aged 70 to 74
with a previous fracture fell from CAN$8 million to
CAN$165,490.
Within the base population, based on a threshold of
CAN$50,000 per QALY, a price reduction of 90% would
be required for denosumab to be optimal. In certain
strata, denosumab would not be optimal even if it had
zero cost. In other strata, the required price reduction
was at least 90%. For zoledronate, the price reduction
would have to be 66% for it to be considered optimal.
Across all strata, the necessary price reduction ranged
from 66% to 85%.
For woman who are intolerant to oral bisphospho-
nates, zoledronate was optimal in the majority of strata.
For zoledronate to be cost-effective in all strata, the nec-
essary price reduction required was 34%. The required
price reduction for denosumab to be optimal in this
Table 4 Sequential Cost Utility Analysis Results for Alternative Patient Populationsa
Age No Previous Fracture Previous Fracture
Patients able to tolerate oral bisphosphonates
65–69 ICER for Z v. A = $1.4 million ICER for Z v. A = $3.1 million
ICER for D v. Z = $7.3 million NT, E, R, and D subject to dominance
NT, E, and R subject to dominance
70–74 ICER for A v. NT = $3,751 ICER for Z v. A = $1.6 million
ICER for Z v. A = $666,285 NT, E, R, and D subject to dominance
ICER for D v. Z = $13.0 million
E and R subject to dominance
75–79 ICER for Z v. A = $816,389 ICER for Z v. A = $5.2 million
NT, E, R, and D subject to dominance NT, E, R, and D subject to dominance
80–84 ICER for Z v. A = $1.1 million A optimal as Z, NT, E, R, and D subject to dominance
NT, E, R, and D subject to dominance
85–89 A optimal as Z, NT, E, R, and D subject to dominance A optimal as Z, NT, E, R, and D subject to dominance
90+ ICER for A v. NT = $2,721 A optimal as Z, NT, E, R, and D subject to dominance
ICER for Z v. A = $1.3 million
E, R, and D subject to dominance
Patients unable to tolerate oral bisphosphonatesb
65–69 ICER for Z v. NT = $94,365 ICER for Z v. NT = $41,374
ICER for D v. Z = $7.3 million D subject to dominance
70–74 ICER for Z v. NT = $83,503 ICER for Z v. NT = $40,956
ICER for D v. Z = $3.0 million D subject to dominance
75–79 ICER for Z v. NT = $63,263 ICER for Z v. NT = $20,408
D subject to dominance D subject to dominance
80–84 ICER for Z v. NT = $48,142 ICER for Z v. NT = $13,484
D subject to dominance D subject to dominance
85–89 ICER for Z v. NT = $51,296 ICER for Z v. NT = $17,770
D subject to dominance D subject to dominance
90+ ICER for Z v. NT = $46,842 ICER for Z v. NT= $17,796
D subject to dominance D subject to dominance
A, alendronate; D, denosumab; E, etidronate; ICER, incremental cost per QALY gained; NT, no therapy; QALY, quality-adjusted life year; R,
risedronate; Z, zoledronate.
aCosts represent CAN$ in 2017.
bComparison of no therapy, denosumab and zoledronate.
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subgroup of women varied by age and fracture history
ranging between 63% and 76%.
Discussion
The aforementioned results suggest that for patients who
are able to tolerate oral bisphosphonates, alendronate is
the optimal treatment regardless of a woman’s age or
fracture history. Although alendronate did not dominate
denosumab and/or zoledronate in all patient strata, the
ICERs for denosumab and zoledronate compared to
alendronate were indicative of them not being cost-effec-
tive. For patients unable to tolerate oral bisphospho-
nates, zoledronate can be considered optimal for a
proportion of women as it was associated with an ICER
of less than CAN$50,000 in the majority of strata (for
women with no previous fracture aged 80–84 or over 90
and for all women with a previous fracture). Denosumab
was either dominated by zoledronate (for women with
no previous fracture aged over 75 and for all women
with a previous fracture) or had an ICER compared to
zoledronate that was indicative of it not being cost-
effective (for women with no previous fracture aged
under 75).
Based on the available literature, this is the first eco-
nomic evaluation comparing such a wide range of osteo-
porotic treatments that is independent of manufacturer
sponsorship. There are a number of publications that have
suggested that manufacturer-sponsored economic evalua-
tions may be susceptible to bias.50,51 Five manufacturer-
sponsored studies were identified and two independent
studies—one comparing denosumab and alendronate and
another comparing anabolic drugs (abaloparatide and teri-
paratide) to no therapy.41,45–48,52,53
The results of this analysis are in contrast to the five
previous studies of denosumab funded by the manufac-
turer. Chau and colleagues reported an incremental cost
per QALY gained of $60,266 (2010 CAN$) for
Table 5 Results of Scenario Analysis for Base Case Populationa
Scenario Sequential Result
Base case ICER for A v. NT = $3,751
ICER for Z v. A = $666,285
ICER for D v. Z = $13.0 million
E and R subject to dominance
Set time = 0 years ICER for A v. NT = $7,972
ICER for Z v. A = $838,746
E, R, and D subject to dominance
Set time = 5 years ICER for Z v. A = $643,327
NT, E, R, and D subject to dominance
Discount rate = 0% I ICER for A v. NT = $2,577
ICER for Z v. A = $608,211
ICER for D v. Z = $8.3 million
E and R subject to dominance
Discount rate = 3% ICER for A v. NT = $5,548
ICER for Z v. A = $800,853
ICER for D v. Z = $47.1 million
E and R subject to dominance
Discount rate = 5% ICER for A v. NT = $6,435
ICER for Z v. A = $839,796
E, R, and D subject to dominance
Inclusion of non-osteoporotic health care costs ICER for A v. NT = $3,749
ICER for Z v. A = $770,725
ICER for D v. Z = $4.8 million
E and R subject to dominance
Scenario analysis favoring denosumabb ICER for D v. A = $165,490
NT and R dominated by A
A, alendronate; D, denosumab; E, etidronate; ICER, incremental cost per QALY gained; NT, no therapy; QALY, quality-adjusted life year; R,
risedronate; Z, zoledronate.
aCosts represent CAN$ in 2017.
bAnalysis compares only no therapy, alendronate, risedronate, and denosumab. Analysis based on assumptions favorable to denosumab relating
to calibration, vertebral facture costs, and mortality and treatment effectiveness adopted in previous manufacturer sponsored studies.
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denosumab versus alendronate for a base case of 72-
year-old women with previous fracture.41 Jönsson and
colleagues reported an incremental cost per QALY
gained of e27,090 (2009 euros) for 71-year-old women
(34% assumed to have a previous fracture).45 Darbà and
colleagues reported an incremental cost per QALY
gained of e16,294 (2013 euros) for 65-year-old women
(28% with previous fracture).46 Parthan and colleagues
reported an ICER of $85,060 per QALY for denosumab
versus alendronate for a cohort of 72-year-old osteo-
porotic women—23% with prevalent vertebral fracture
(2012 US$). Finally, Hiligsmann and Reginster reported
an ICER of e14,166 per QALY for a 70-year-old osteo-
porotic women with previous vertebral fracture (2009
euros).48
All of the above findings contrast with our result that
denosumab was either dominated by alendronate or was
associated with a much higher ICER. The difference in
results between the studies and the current analysis may
be due to four issues. First, it is unclear that the
manufacturer-sponsored studies adequately accounted
for calibration especially in relation to mortality.
Second, the studies used similar estimates of effectiveness
that did not incorporate all older clinical trials for oral
bisphosphonates. The choice of effectiveness data
favored denosumab especially in terms of reductions in
hip fractures. Third, the studies made the assumption
that the increase in mortality associated with vertebral
fractures was either greater or equal to that associated
with hip fractures. Finally, the studies assumed much
higher costs associated with vertebral fractures, in some
instances exceeding those of hip fractures.
A scenario analysis attempted to address these issues
by assuming efficacy as used within the manufacturer
sponsored studies; equal mortality associated hip and
vertebral fractures; higher costs associated with vertebral
fractures; and by not calibrating mortality data. This
analysis found an ICER for denosumab versus alendro-
nate of $165,490: closer to the various manufacturers’
estimates.
An independent analysis by Karnon and colleagues
found that denosumab was not cost-effective compared
to alendronate with an estimated ICER for denosumab
versus alendronate of $246,749 per QALY (AUS$
unknown date).52 This analysis differed from the current
analysis in two ways. First, it modelled the effectiveness
of treatment through changes in BMD rather than frac-
ture prevention. Second, it assumed a much lower cost
of denosumab based on current Australian funding of
denosumab which fixed the cost to be similar to branded
alendronate.
A recent independent study from the Institute of
Clinical and Economic Review focused on anabolic
therapies for postmenopausal osteoporosis.53 Thus,
given the comparators, the results are not directly related
to the current study. However, the methods adopted and
the assumptions made in the current study are consistent
with approach adopted by this independent report.
In Ontario under the Ontario Drug Formulary, fund-
ing for denosumab is restricted to women who experi-
ence significant decline in BMD after 1 year continuous
bisphosphonate therapy or are unable to tolerate oral
bisphosphonates due to either hypersensitivity or
abnormalities of the esophagus. For both criteria,
woman must also meet two of three criteria: age over 75,
be osteoporotic (a BMD T-score less than or equal to
22.5), and/or have a previous osteoporotic fracture.
Funding for zoledronate is restricted to women who are
unable to tolerate oral bisphosphonates due to the same
reasons and who meet the same criteria as for denosu-
mab. Despite these limited access criteria, expenditure on
denosumab in 2015–2016 in Ontario was CAN$34.79
million—suggesting the equivalent of over 47,000 annual
users in Ontario.54 For risedronate, annual expenditure
of the data suggested 88,000 users. Data for alendronate
were unavailable for 2015–2016 but for 2013–2014, the
data suggests over 110,000 users.55
There is the potential that provincial drug plans may
have negotiated lower prices for zoledronate and denosu-
mab though those prices remain confidential. Threshold
analysis was conducted and demonstrated that the costs
of denosumab and zoledronate needed to be reduced sub-
stantially to allow these therapies to become optimal for
treating all osteoporotic women. When limiting these
products to those unable to tolerate oral bisphospho-
nates, the current costs of zoledronate is such that it is
cost-effective for treating a high proportion of women
who fall into this indication. However, the cost of deno-
sumab would need to be reduced substantially for it to be
cost-effective even in this small subgroup of women.
It is unclear what the true incidence of intolerance to
oral bisphosphonates is. In one randomized controlled
trial of once weekly alendronate compared to placebo,
the percentage of patients reporting an upper gastroin-
testinal tract adverse event was lower for alendronate
patients (11%) than for placebo (13%).56 The probability
that a patient on alendronate would discontinue due to
such an event was 3%. These findings suggest that only a
small percentage of osteoporotic women fall in to this
subgroup.
The recent Canadian guidelines are consistent in
clearly recommending health care system perspective as
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the primary analysis based on its relevance to the deci-
sion problem. Thus, for the current analyses, it would
not be appropriate to consider the societal perspective as
it has been consistently shown that this is not considered
of relevance to provincial decision makers. Adoption of
the societal perspective assumes that health care decision
makers would be willing to trade health gains for bene-
fits to other sectors. Thus, the choice of the health care
system perspective is not a limitation as such. It should
be noted that as the population of interest is greater than
65 the likely impacts on productivity will be minimal and
results from the societal perspective would likely be simi-
lar to current results.
The current study does, however, have a number of
limitations. First, there is a lack of head to head clinical
trials and thus analysis relied on effectiveness data from
an indirect treatment comparison of randomized con-
trolled trials the majority of which were placebo con-
trolled rather than active comparators. It would be
beneficial that future novel treatments for osteoporosis
are compared with current existing therapies especially
oral bisphosphonates, which are available in low-cost
generic format.
Second, analysis used fracture prevalence data from
2009. It is assumed that prevalence has not changed
greatly but a re-analysis should be conducted if more
temporaneous data become available.
Third, a detailed stratified analysis is conducted as per
the recent Canadian guidelines for economic evaluation.
For many data elements strata-specific data are available
but for some the assumption needed to be made that data
did not vary by strata. That is a limitation, and should
further strata-specific data become available then a rea-
nalysis would be justified.
Fourth, for zoledronate, the effect on wrist fractures is
not reported in any clinical trial for postmenopausal
women. This is surprising as such data may have been
collected within the clinical trials but not reported.
Within this analysis it was assumed that the risk of wrist
fracture with zoledronate was the same as for no therapy.
Additionally, analysis is based on the assumption that
individuals will not undergo sequential treatment with
oral bisphosphonates. Thus, the decision problem relates
to what would be the optimal treatment for osteoporosis
rather than the optimal sequence of treatments. The
results of the analysis suggest that the only oral bispho-
sphonate likely to be cost-effective is alendronate.
Furthermore, the analysis suggest that for those unable
to tolerate oral bisphosphonates only zoledronate is
cost-effective in those with previous fracture. Thus, if
sequencing of treatment was necessary for patients who
experience a fracture on therapy, the optimal sequence
of treatments for postmenopausal osteoporosis is likely
to be alendronate followed by zoledronate post fracture.
Finally, costs were based on the most recent available
Canadian data, and drug costs were obtained from the
Ontario drug formulary. This may be seen as a limita-
tion. Although drug costs may vary by provincial formu-
lary, it is unlikely that list prices would vary substantially
enough to alter the conclusions of this analysis.
In conclusion, this study demonstrated that, based on
the currently available data, treatment with alendronate
is the optimal strategy for women who are able to toler-
ate oral bisphosphonates. For women unable to tolerate
oral bisphosphonates, zoledronate is optimal for a high
proportion of women. The required price reductions to
lead to denosumab being cost-effective in either group
were substantial.
Thus, the policy implications from this analysis is that
denosumab should not be covered under provincial drug
formularies for the general osteoporotic population
unless substantial price reductions can be negotiated.
Zoledronate should be covered but this should continue
to be restricted to women who are truly intolerant to
weekly oral bisphosphonate therapy.
Supplemental Material
The online supplementary appendix for this article is available
on the Medical Decision Making Policy & Practice website at
http://journals.sagepub.com/home/mpp.
References
1. World Health Organization. The Assessment of Osteoporo-
sis at Primary Health Care Level. Geneva: World Health
Organization; 2007.
2. Qaseem A, Forciea MA, Mclean RM, Denberg TD; Clini-
cal Guidelines Committee of the American College of Phy-
sicians. Treatment of low bone density or osteoporosis to
prevent fractures in men and women: a clinical practice
guideline update from the American College of Physicians.
Ann Intern Med. 2017;166(11):818–39. doi:10.7326/M15-
1361
3. Tenenhouse A, Joseph L, Kreiger N, et al. Estimation of
the prevalence of low bone density in Canadian women
and men using a population-specific DXA reference stan-
dard: the Canadian Multicentre Osteoporosis Study
(CaMos). Osteoporos Int. 2000;11(10):897–904.
4. Tarride J, Hopkins RB, Leslie WD, et al. The burden of
illness of osteoporosis in Canada. Osteoporos Int.
2012;23(11):2591–600. doi:10.1007/s00198-012-1931-z
5. Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-
analysis: excess mortality after hip fracture among older
14 MDM Policy & Practice 00(0)
women and men. Ann Intern Med. 2010;152(6):380–90.
doi:10.1059/0003-4819-152-6-201003160-00008
6. Lix LM, Azimaee M, Osman BA, et al. Osteoporosis-
related fracture case definitions for population-based
administrative data. BMC Public Health. 2012;12:301.
7. Marshall D, Johnell O, Wedel H. Meta-analysis of how
well measures of bone mineral density predict occurrence
of osteoporotic fractures. BMJ. 1996;312(7041):1254–59.
8. Canadian Agency for Drugs and Technologies in Health.
Guidelines for the Economic Evaluation of Health Technolo-
gies: Canada. 4th ed. Ottawa: Canadian Agency for Drugs
and Technologies in Health; 2017.
9. Canadian Agency for Drugs and Technologies in Health.
Guidelines for the Economic Evaluation of Health Technolo-
gies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs
and Technologies in Health; 2006.
10. Coyle D, Buxton MJ, O’Brien BJ. Stratified cost-
effectiveness analysis: a framework for establishing effi-
cient limited use criteria. Health Econ. 2003;12(5):421–7.
doi:10.1002/hec.788
11. Espinoza MA, Manca A, Claxton K, Sculpher MJ. The
value of heterogeneity for cost-effectiveness subgroup anal-
ysis: conceptual framework and application. Med Decis
Mak. 2014;34(8):951–64. doi:10.1177/0272989X14538705
12. Paulden M, Galvanni V, Chakraborty S, Kudinga B,
McCabe C. Discounting and the Evaluation of Health Care
Programs. Ottawa: Canadian Agency for Drugs and Tech-
nologies in Health; 2016.
13. Waldegger L, Cranney A, Man-son-hing M, Coyle D.
Cost-effectiveness of hip protectors in institutional dwell-
ing elderly. Osteoporos Int. 2003;14(3):243–50. doi:10.1007/
s00198-002-1354-3
14. Coyle D, Tahar AH, Murphy G, et al. Teriparatide and
Bisphosphonates for Treatment of Osteoporosis in Women:
A Clinical and Economic Analysis. Ottawa: Canadian
Agency for Drugs and Technologies in Health; 2006.
15. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P. Cost
effectiveness of nasal calcitonin in postmenopausal women:
use of Cochrane Collaboration methods for meta-analysis
within economic evaluation. Pharmacoeconomics. 2001;19(5
Pt. 2):565–75.
16. Coyle D, Tosteson AN. Towards a reference case for eco-
nomic evaluation of osteoporosis treatments. J Rheumatol
Suppl. 2003;68:31–6.
17. Gandjour A, Weyler E. Cost-effectiveness of preventing
hip fractures by hip protectors in elderly institutionalized
residents in Germany. Value Health. 2008;11(7):1088–95.
doi:10.1111/j.1524-4733.2008.00393.x
18. Nikitovic M. Direct Costs of Hip Fractures Among Seniors
in Ontario. Toronto: University of Toronto; 2011.
19. Nikitovic M, Wodchis W, Krahn M, Cadarette S. Direct
health-care costs attributed to hip fractures among seniors:
a matched cohort study. Osteoporos Int. 2013;24(2):659–69.
doi:10.1007/s00198-012-2034-6
20. Ontario Case Costing Initiative. Health Data Branch web
portal. Available from: https://hsim.health.gov.on.ca/
hdbportal/
21. Nshimyumukiza L, Durand A, Gagnon M, et al. An eco-
nomic evaluation: simulation of the cost-effectiveness and
cost-utility of universal prevention strategies against
osteoporosis-related fractures. J Bone Miner Res. 2013;28(2):
383–94. doi:10.1002/jbmr.1758
22. Ontario Ministry of Health and Long-Term Care. Ontario
Drug Benefit Formulary/Comparative Drug Index. 42nd ed.
Toronto: Ontario Ministry of Health and Long-Term Care;
2017.
23. Statistics Canada. Canadian Community Health Survey—
Annual Component (CCHS). Detailed Information for
2014. Ottawa: Statistics Canada; 2015.
24. Peasgood T, Herrmann K, Kanis JA, Brazier JE. An
updated systematic review of health state utility values for
osteoporosis related conditions. Osteoporos Int. 2009;20(6):
853–68. doi:10.1007/s00198-009-0844-y
25. Oleksik A, Lips P, Dawson A, et al. Health-related quality
of life in postmenopausal women with low BMD with or
without prevalent vertebral fractures. J Bone Miner Res.
2000;15(7):1384–92.
26. Hopkins RB, Goeree R, Pullenayegum E, et al. The relative
efficacy of nine osteoporosis medications for reducing the
rate of fractures in post-menopausal women. BMC Muscu-
loskelet Disord. 2011;12:209. doi:10.1186/1471-2474-12-209
27. Emkey RD, Ettinger M. Improving compliance and persis-
tence with bisphosphonate therapy for osteoporosis. Am J
Med. 2006;119(4 Suppl. 1):S18–S24. doi:10.1016/j.amj
med.2005.12.019
28. Freemantle N, Satram-Hoang S, Tang ET, et al. Final
results of the DAPS (Denosumab Adherence Preference
Satisfaction) study: a 24-month, randomized, crossover
comparison with alendronate in postmenopausal women.
Osteoporos Int. 2012;23(1):317–26. doi:10.1007/s00198-
011-1780-1
29. Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Har-
ris ST. Frequency of discontinuation of injectable osteo-
porosis therapies in US patients over 2 years. Osteoporos
Int. 2017;28(4):1355–63. doi:10.1007/s00198-016-3886-y
30. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA
3rd, Berger M. Patients with prior fractures have an
increased risk of future fractures: a summary of the litera-
ture and statistical synthesis. J Bone Miner Res. 2000;15(4):
721–39.
31. Crilly RG, Tanner DA, Kloseck M, Chesworth BM. Hip
fractures in long-term care: is the excess explained by the
age and gender distribution of the residents? J Aging Res.
2010;2010:291258. doi:10.4061/2010/291258
32. Statistics Canada. Living Arrangements of Seniors. Families,
Households and Marital Status. Structural Type of Dwelling
and Collectives, 2011 Census of Population. Ottawa: Statis-
tics Canada; 2013.
Coyle 15
33. Statistics Canada. Life Tables, Canada, Provinces and Terri-
tories. Tables: 84-537-X. Ottawa: Statistics Canada; 2017.
34. Holvik K, Ranhoff AH, Martinsen MI, Solheim LF. Pre-
dictors of mortality in older hip fracture inpatients admit-
ted to an orthogeriatric unit in Oslo, Norway. J Aging
Health. 2010;22(8):1114–31. doi:10.1177/0898264310378
040
35. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant
HK, Cummings SR. Vertebral fractures and mortality in
older women: a prospective study. Study of Osteoporotic
Fractures Research Group. Arch Intern Med. 2017;159(11):
1215–20.
36. Coyle D, Lee KM, Cooper NJ. Use of evidence in decision
models. In: Shemilt I, Mugford M, Vale L, Marsh K,
Donaldson C, eds. Evidence-Based Decisions and Econom-
ics Health Care, Social Welfare, Education and Criminal
Justice. 2nd ed. Oxford: Blackwell; 2010.
37. Ontario Ministry of Health and Long-Term Care. Ontario
Case Costing Initiative (OCCI). Available from: https://
www.ontario.ca/data/ontario-case-costing-initiative-occi
38. Ontario Ministry of Health and Long-Term Care. Sched-
ule of benefits: physician services under the Health Insur-
ance Act. Available from: http://www.health.gov.on.ca/en/
pro/programs/ohip/sob/physserv/sob_master11062015.pdf
39. Simon JA, Recknor C, Moffett AH Jr, et al. Impact of
denosumab on the peripheral skeleton of postmenopausal
women with osteoporosis: bone density, mass, and strength
of the radius, and wrist fracture. Menopause. 2013;20(2):
130–7. doi:10.1097/gme.0b013e318267f909
40. Cummings S, San Martin J, McClung M, et al. Denosumab
for prevention of fractures in postmenopausal women with
osteoporosis. N Engl J Med. 2009;361(8):756–75.
41. Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi
JD, Goeree R. Cost-effectiveness of denosumab in the
treatment of postmenopausal osteoporosis in Canada. J
Med Econ. 2012;15(Suppl. 1):3–14. doi:10.3111/13696998
.2012.737393
42. Tosteson A, Jönsson B, Grima D, O’Brien B, Black D,
Adachi J. Challenges for model-based economic evalua-
tions of postmenopausal osteoporosis interventions. Osteo-
poros Int. 2001;12(10):849–57.
43. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits
of alendronate: 7-year treatment of postmenopausal osteo-
porotic women. Phase III Osteoporosis Treatment Study
Group. J Clin Endocrinol Metab. 2017;85(9):3109–15.
44. Edlin R, McCabe C, Hulme C, Hall P, Wright J. Cost
Effectiveness Modelling for Health Technology Assessment.
Basel: Springer International; 2015.
45. Jönsson B, Ström O, Eisman J, et al. Cost-effectiveness of
denosumab for the treatment of postmenopausal osteo-
porosis. Osteoporos Int. 2016;22(3):967–82. doi:10.1007/s0
0198-010-1424-x
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